ESMO PRECEPTORSHIP PROGRAMME
PROSTATE CANCER

Multidisciplinary management, standards of care, therapeutic targets and future perspectives

Hong Kong SAR, China
13-14 January 2027

CO-CHAIRS
Barbara A. Jereczek-Fossa, Italy
Darren Poon, Hong Kong SAR, China

SPEAKERS
Matthew Chiu, Hong Kong SAR, China
Peter Chiu, Hong Kong SAR, China
Louise Emmett, Australia
Peter Fong, New Zealand
Deborah Mukherji, United Arab Emirates
Kenrick Ng, United Kingdom
Marniza Binti Saad, Malaysia
Yüksel Ürün, Türkiye

LEARNING OBJECTIVES

- To learn about fundamentals of epidemiology, natural history, and diagnosis as contributing factors to heterogeneity in prostate cancer
- To understand essentials in the assessment and multidisciplinary treatment of prostate cancer
- To learn about advances in treatment and novel targets in prostate cancer

ACCREDITATION

The programme of this event has been accredited with **9 ESMO-MORA category 1 points**.
Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to esmo.org.

ACKNOWLEDGEMENTS

AstraZeneca has provided a sponsorship grant towards this independent Programme

ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4, 6900 Lugano, Switzerland
Email: courses@esmo.org
www.esmo.org

Wednesday, 13 January 2027

09:00-09:10 10’	Opening and welcome	
10’	Welcome from ESMO - Objectives and scientific introduction	Barbara A. Jereczek-Fossa, IT Darren Poon, HK SAR, CN

09:10-10:50 100’	SESSION 1 Screening, Diagnosis, Staging and Localised Prostate Cancer	Chair: Barbara A. Jereczek-Fossa, IT
15’	PSA screening and diagnosis	Peter Chiu, HK SAR, CN
10’	Staging	Louise Emmett, AU
15’	Clinician’s perspectives on common and uncommon prostate cancer histology	Marniza Binti Saad, MY
15’	Treatment of localised prostate cancer according to risk category	Barbara A. Jereczek-Fossa, IT
15’	Radiotherapeutic approaches for localised prostate cancer	Darren Poon, HK SAR, CN
15’	Q&A	All
15’	Participants clinical case discussion (1x15’)	Faculty

10:50-11:20	Coffee break

11:20-12:45 85’	SESSION 2 Biochemical Relapse	Chair: Barbara A. Jereczek-Fossa, IT
15’	Biochemical relapse: Definition and diagnostic algorithm	Barbara A. Jereczek-Fossa, IT
20’	Rising PSA after radical local treatment: Prognosis, indications for salvage local treatments, salvage vs adjuvant treatments	Darren Poon, HK SAR, CN
20’	Early vs deferred systemic treatment in high-risk localised prostate cancer and biochemical failure	Peter Chiu, HK SAR, CN
15’	Q&A	All
15’	Participants clinical case discussion (1x15’)	Faculty

12:45-13:45	Lunch

13:45-15:30 105’	SESSION 3 Systemic Treatment Options and Molecular Characterisation	Chair: Darren Poon, HK SAR, CN
20’	ADT and other hormonal treatments: Mechanisms of action, efficacy and toxicities	Yüksel Ürün, TR
20’	Chemotherapy, PARP inhibitors and Radium-223: Mechanisms of action, efficacy and toxicities	Kenrick Ng, UK
15’	Bone health agents: Mechanism of action, efficacy and toxicities	Deborah Mukherji, UAE
20’	Molecular characterisation: Germline and somatic testing	Peter Fong, NZ
15’	Q&A	All
15’	Participants clinical case discussion (1x15’)	Faculty

15:30-16:00	Coffee break	
16:00-17:25 85'	**SESSION 4 Castration-Sensitive Metastatic Prostate Cancer**	**Chair: Darren Poon, HK SAR, CN**
20'	Metastatic castration-sensitive prostate cancer (mCSPC): Doublets	Deborah Mukherji, UAE
20'	Triplet and quadruplet options (mCSPC)	Yüksel Ürün, TR
15'	Oligometastatic CSPC disease: Which treatment?	Matthew Chiu, HK SAR, CN
15'	Q&A	All
15'	Participants clinical case discussion (1x15')	Faculty
19:00	Networking dinner	

Thursday, 14 January 2027

09:00-10:40 100'	**SESSION 5 Non-metastatic and Metastatic Castration-Resistant Disease**	**Chair: Barbara A. Jereczek-Fossa, IT**
20'	Non-metastatic and oligometastatic CRPC: Current treatment	Kenrick Ng, UK
20'	Metastatic CRPC: Current treatment	Marniza Binti Saad, MY
20'	PSMA-based therapies	Louise Emmett, AU
10'	Q&A	All
30'	Participants clinical case discussion (2x15')	Faculty
10:40-11:10	Coffee break	
11:10-12:15 65'	**SESSION 6 Metastatic Castration-Resistant Disease**	**Chair: Darren Poon, HK SAR, CN**
15'	Treatment in frail patients with mCRPC	Peter Fong, NZ
20'	Experimental treatments for mCRPC	Matthew Chiu, HK SAR, CN
15'	Q&A	All
15'	Participants clinical case discussion (1x15')	Faculty
12:15-12:25 10'	**Conclusion and farewell**	**Barbara A. Jereczek-Fossa, IT Darren Poon, HK SAR, CN**
12:25-13:25	Lunch	

Note: Each 15-minute slot for clinical case discussion includes a 7' case presentation and an 8' Q&A / panel discussion